Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more
Immutep Ltd (IMM) - Net Assets
Latest net assets as of June 2025: AU$143.64 Million AUD
Based on the latest financial reports, Immutep Ltd (IMM) has net assets worth AU$143.64 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$156.98 Million) and total liabilities (AU$13.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$143.64 Million |
| % of Total Assets | 91.5% |
| Annual Growth Rate | 18.95% |
| 5-Year Change | 96.03% |
| 10-Year Change | 306.7% |
| Growth Volatility | 169.37 |
Immutep Ltd - Net Assets Trend (2000–2025)
This chart illustrates how Immutep Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immutep Ltd (2000–2025)
The table below shows the annual net assets of Immutep Ltd from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$143.64 Million | -24.21% |
| 2024-06-30 | AU$189.52 Million | +38.87% |
| 2023-06-30 | AU$136.47 Million | +45.06% |
| 2022-06-30 | AU$94.08 Million | +28.40% |
| 2021-06-30 | AU$73.27 Million | +120.04% |
| 2020-06-30 | AU$33.30 Million | +36.54% |
| 2019-06-30 | AU$24.39 Million | -27.25% |
| 2018-06-30 | AU$33.52 Million | +26.34% |
| 2017-06-30 | AU$26.53 Million | -24.87% |
| 2016-06-30 | AU$35.32 Million | +43.05% |
| 2015-06-30 | AU$24.69 Million | +9.28% |
| 2014-06-30 | AU$22.59 Million | -22.76% |
| 2013-06-30 | AU$29.25 Million | -21.29% |
| 2012-06-30 | AU$37.16 Million | -32.56% |
| 2011-06-30 | AU$55.10 Million | +228.21% |
| 2010-06-30 | AU$16.79 Million | +826.20% |
| 2009-06-30 | AU$1.81 Million | -31.17% |
| 2008-06-30 | AU$2.63 Million | -35.46% |
| 2007-06-30 | AU$4.08 Million | -35.41% |
| 2006-06-30 | AU$6.32 Million | -24.29% |
| 2005-06-30 | AU$8.34 Million | +62.76% |
| 2004-06-30 | AU$5.13 Million | +65.73% |
| 2003-06-30 | AU$3.09 Million | -43.35% |
| 2002-06-30 | AU$5.46 Million | +31.82% |
| 2001-06-30 | AU$4.14 Million | +120.79% |
| 2000-06-30 | AU$1.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immutep Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44408132200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$535.07 Million | 372.52% |
| Other Comprehensive Income | AU$52.65 Million | 36.65% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$143.64 Million | 100.00% |
Immutep Ltd Competitors by Market Cap
The table below lists competitors of Immutep Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Provision Information Co.Ltd.
TWO:6590
|
$38.59 Million |
|
OCI International Holdings Limited
PINK:DGTLF
|
$38.60 Million |
|
theglobe.com Inc
PINK:TGLO
|
$38.60 Million |
|
BitNine Co. Ltd.
KQ:357880
|
$38.60 Million |
|
SinoMedia Holding Limited
F:SJY
|
$38.58 Million |
|
Knaus Tabbert AG
XETRA:KTA
|
$38.57 Million |
|
Precious Shipping Public Company Limited
PINK:PSGFF
|
$38.56 Million |
|
PAMT CORP
NASDAQ:PAMT
|
$38.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immutep Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 189,521,742 to 143,635,363, a change of -45,886,379 (-24.2%).
- Net loss of 61,434,165 reduced equity.
- Other comprehensive income increased equity by 22,583,096.
- Other factors decreased equity by 7,035,310.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-61.43 Million | -42.77% |
| Other Comprehensive Income | AU$22.58 Million | +15.72% |
| Other Changes | AU$-7.04 Million | -4.9% |
| Total Change | AU$- | -24.21% |
Book Value vs Market Value Analysis
This analysis compares Immutep Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.09x to 0.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | AU$0.57 | AU$0.05 | x |
| 2005-06-30 | AU$0.52 | AU$0.05 | x |
| 2006-06-30 | AU$0.27 | AU$0.05 | x |
| 2007-06-30 | AU$0.16 | AU$0.05 | x |
| 2008-06-30 | AU$0.01 | AU$0.05 | x |
| 2009-06-30 | AU$0.00 | AU$0.05 | x |
| 2010-06-30 | AU$0.04 | AU$0.05 | x |
| 2011-06-30 | AU$0.13 | AU$0.05 | x |
| 2012-06-30 | AU$0.09 | AU$0.05 | x |
| 2013-06-30 | AU$0.07 | AU$0.05 | x |
| 2014-06-30 | AU$0.05 | AU$0.05 | x |
| 2015-06-30 | AU$0.06 | AU$0.05 | x |
| 2016-06-30 | AU$0.15 | AU$0.05 | x |
| 2017-06-30 | AU$0.13 | AU$0.05 | x |
| 2018-06-30 | AU$0.13 | AU$0.05 | x |
| 2019-06-30 | AU$0.07 | AU$0.05 | x |
| 2020-06-30 | AU$0.08 | AU$0.05 | x |
| 2021-06-30 | AU$0.12 | AU$0.05 | x |
| 2022-06-30 | AU$0.11 | AU$0.05 | x |
| 2023-06-30 | AU$0.16 | AU$0.05 | x |
| 2024-06-30 | AU$0.16 | AU$0.05 | x |
| 2025-06-30 | AU$0.10 | AU$0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immutep Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1218.02%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.09x
- Recent ROE (-42.77%) is above the historical average (-67.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -98.09% | -1411.65% | 0.06x | 1.14x | AU$-5.48 Million |
| 2005 | -75.43% | -1114.93% | 0.06x | 1.09x | AU$-7.13 Million |
| 2006 | -67.34% | -2797.82% | 0.02x | 1.17x | AU$-4.89 Million |
| 2007 | -76.94% | -13647726.09% | 0.00x | 1.07x | AU$-3.55 Million |
| 2008 | -71.67% | -3254.06% | 0.02x | 1.07x | AU$-2.15 Million |
| 2009 | -162.53% | -10159.85% | 0.01x | 1.37x | AU$-3.13 Million |
| 2010 | -72.43% | -2321.57% | 0.03x | 1.13x | AU$-13.84 Million |
| 2011 | -38.26% | -1977.59% | 0.02x | 1.05x | AU$-26.59 Million |
| 2012 | -53.67% | -1311.89% | 0.04x | 1.12x | AU$-23.66 Million |
| 2013 | -52.06% | -496.54% | 0.09x | 1.12x | AU$-18.15 Million |
| 2014 | -59.06% | -549.84% | 0.10x | 1.12x | AU$-15.60 Million |
| 2015 | -130.22% | -1715.89% | 0.06x | 1.25x | AU$-34.62 Million |
| 2016 | -175.59% | -35426.72% | 0.00x | 1.20x | AU$-65.55 Million |
| 2017 | -35.30% | -227.54% | 0.12x | 1.32x | AU$-12.02 Million |
| 2018 | -38.02% | -484.55% | 0.06x | 1.40x | AU$-16.10 Million |
| 2019 | -66.72% | -11640.01% | 0.00x | 1.66x | AU$-18.71 Million |
| 2020 | -40.45% | -179.90% | 0.16x | 1.40x | AU$-16.80 Million |
| 2021 | -40.81% | -774.12% | 0.05x | 1.12x | AU$-37.23 Million |
| 2022 | -34.24% | -18906.51% | 0.00x | 1.09x | AU$-41.62 Million |
| 2023 | -29.23% | -1138.04% | 0.02x | 1.08x | AU$-53.54 Million |
| 2024 | -22.54% | -1111.84% | 0.02x | 1.06x | AU$-61.67 Million |
| 2025 | -42.77% | -1218.02% | 0.03x | 1.09x | AU$-75.80 Million |
Industry Comparison
This section compares Immutep Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immutep Ltd (IMM) | AU$143.64 Million | -98.09% | 0.09x | $38.59 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |